Farallon Capital Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Farallon Capital Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-237,200	Closed	-$11.7M	–	118
2015 Q2	$11.7M	Buy	237,200 +90,500	+62%	+$5.41M	0.16%	65
2015 Q1	$11.5M	Sell	146,700 -47,000	-24%	-$2.92M	0.17%	64
2014 Q4	$11.7M	Sell	193,700 -74,730	-28%	-$3.75M	0.16%	65
2014 Q3	$11.4M	Hold	268,430	–	–	0.18%	65
2014 Q2	$16.6M	Hold	268,430	–	–	0.24%	59
2014 Q1	$17.4M	Buy	268,430 +107,930	+67%	+$7.3M	0.34%	52
2013 Q4	$9.04M	Buy	160,500 +65,500	+69%	+$3.68M	0.19%	61
2013 Q3	$5.83M	Hold	95,000	–	–	0.12%	63
2013 Q2	$5.56M	Buy	+95,000	New	+$5.84M	0.11%	64

Other funds holding OREX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Farallon Capital Management's OREX Position: Q3 2015 in Review

Farallon Capital Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2015, closing a stake of 237,200 shares — an estimated $11.7M sold.

Farallon Capital Management first reported a position in OREX in Q2 2013 and held it in 9 quarters. The position peaked at $17.4M in Q1 2014. 132 funds tracked by Wall St. Rank hold OREX as of Q3 2015.

Farallon Capital Management reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
Farallon Capital Management sold 237,200 Orexigen Therapeutics, Inc. shares in Q3 2015, an estimated $11.7M.
Farallon Capital Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 9 quarters.
Farallon Capital Management's Orexigen Therapeutics, Inc. position peaked at $17.4M in Q1 2014.
132 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2015.

Based on Farallon Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.